23 April 2019 | News
The collaboration between Elpiscience and Bio-Techne will expand mutual capabilities in the field of cancer immunotherapy.
image credit- shuttershock.com
Elpiscience BioPharma and Bio-Techne Corporation have announced that the companies have entered into a strategic collaboration for the development of anti-cancer therapeutics.
Under the terms of the agreement, Elpiscience will have access to multiple antibodies from Bio-Techne's extensive product portfolio for use in the development of preclinical, clinical, and commercial biopharmaceuticals.
The collaboration between Elpiscience, a China based biotech company committed to leading the innovation and development of the next generation of cancer immunotherapy, and Bio-Techne, a global leader in life sciences and molecular diagnostics, will expand mutual capabilities in the field of cancer immunotherapy.
This strategic collaboration also aims to accelerate the development of new biologics to address unmet medical needs in oncology.